Molly Grammel

Molly R. Grammel

Molly R. Grammel
+1 617 570 8112

Molly Grammel is a partner in Goodwin’s Intellectual Property Litigation practice and is a member of the firm’s Life Sciences Disputes group. She has extensive federal trial experience in cutting-edge technology IP litigation that spans a diverse set of industries, including biologic and biosimilar drugs and artificial intelligence and machine learning.  Ms. Grammel is a go-to partner for managing complex, high stakes matters, including numerous representations involving products with > $1 billion annual U.S. sales. Ms. Grammel specializes in providing clients with business-focused counseling regarding litigation strategy and developing and executing substantive legal theories through stand-up roles in court. She is a practiced courtroom advocate who has taken numerous patent cases to trial before juries and judges in federal district courts across the country and up on appeal to the Federal Circuit.

Ms. Grammel also has extensive representing Patent Owners and Petitioners in post-grant challenges before the Patent Trial and Appeal Board of the United States Patent and Trademark Office.  


At Goodwin, Ms. Grammel has been an active member of teams litigating three federal jury trials, one federal bench trial, and one federal preliminary injunction hearing. She has also worked on appellate matters in the Federal Circuit, the First Circuit, and the Supreme Judicial Court of Massachusetts, as well as inter partes review proceedings.

Representative matters include:

  • Novartis Vaccines and Diagnostics, Inc. et al. v. Genentech, Inc., C.A. No. 21-04874-EJD (N.D. Cal.); representing Novartis in antibody engineering patent license dispute relating to Novartis’s Cosentyx® and Ilaris® products, seeking $209.5 million in damages.
  • Teva Pharmaceuticals International GmbH et al. v. Eli Lilly and Company, C.A. Nos. 18-12029-ADB, 21-10954-ADB (D. Mass.); representing Teva in two suits asserting Teva method of treatment patents regarding anti-CGRP antibodies against Eli Lilly’s Emgality® (galcanezumab) product.
  • Staley et al v. Gilead Sciences, Inc. et al., C.A. No. 19-02573-EMC (N.D. Cal.) and various other suits in N.D. Cal. and New Mexico and Pennsylvania trial courts; representing Teva Pharmaceuticals in antitrust suits challenging prior settlement of Hatch Waxman patent litigation brought by Gilead regarding Teva’s generic versions of Viread® (tenofovir), Truvada® (tenofovir/emtricitabine), and Atripla® (tenofovir/emtricitamine/efavirenz).  Relevant patents include compound, enantiomer, and formulation claims.
  • Certain Pre-Filled Syringes for Intravitreal Injection and Components Thereof, Inv. No. 337-TA-1207 (USITC); Novartis Pharma AG et al v. Regeneron Pharmaceuticals, Inc., C.A. No. 20-00690-DNH (N.D.N.Y.); Regeneron Pharmaceuticals, Inc. v. Novartis Pharma AG, et al., IPR2020-01317, IPR2020-01318, IPR2021-00816 (P.T.A.B.). Represented Novartis in ITC investigation and related litigations and inter partes review proceedings relating to assertion of Novartis’s pre-filled syringe patent against Regeneron’s blockbuster EYLEA® (aflibercept) product.
  • Manufacturing Resources Int’l, Inc. v. Civiq Smartscapes, LLC et al., C.A. No. 17-269-RGA (D. Del.). Represented defendants against pending claims of patent infringement, trademark infringement, and unfair competition and deceptive trade practices claims relating to digital outdoor displays. Successfully obtained dismissal with prejudice of 13 asserted patents as well as all trademark infringement claims and favorable settlement regarding remaining claims. Asserted patents included digital display system and cooling method claims.
  • Genentech, Inc. et al. v. Celltrion, Inc. et al., C.A. Nos. 18-95-CFC, 18-1025-CFC (D. Del.). Represented Celltrion and Teva in BPCIA dispute regarding proposed biosimilar to HERCEPTIN® involving 40 patents, including during the pre-suit patent dance and during ensuing litigation. Asserted patents included antibody manufacturing process, method of treatment and diagnostic method claims.
  • Reckitt Benckiser Pharmaceuticals Inc. et al. v. Dr. Reddy’s Laboratories, S.A. et al., C.A. Nos. 17-7111-KM, 18-1775-KM, 18-5288-KM (D.N.J.). Represented Dr. Reddy’s in second-wave infringement suit regarding Dr. Reddy’s proposed generic versions of SUBOXONE® (buprenorphine/naloxone) sublingual films, including during preliminary injunction proceedings and successful expedited appeal therefrom, resulting in a finding by the Federal Circuit that the district court committed legal error and abused its discretion in entering an injunction, and that one of the plaintiffs’ second-wave infringement cases is likely barred by claim preclusion.  The case concluded with a favorable settlement under which Dr. Reddy’s received $72 million.
  • Reckitt Benckiser Pharmaceuticals Inc. et al. v. Dr. Reddy’s Laboratories, S.A. et al., No. 14-1451-RGA (D. Del.). Represented Dr. Reddy’s in Hatch-Waxman suit regarding Dr. Reddy’s proposed generic versions of SUBOXONE® (buprenorphine/naloxone) sublingual films, resulting in trial judgment of non-infringement of all asserted claims, which was affirmed by the Federal Circuit on appeal. Directed a witness at trial and had substantial involvement in development and presentation of noninfringement defenses before and at trial. Asserted patents included pharmaceutical thin film formulation and manufacturing process claims.
  • Veracode, Inc. et al v. Appthority, Inc., No. 12-10487-DPW (D. Mass.). Represented patent owner in infringement suit against a competitor asserting patents relating to analysis and review of source code, resulting in jury verdict and post-trial judgment as a matter of law of willful infringement and entry of a permanent injunction.
  • Various non-public representations, including advising global innovator pharmaceutical company contemplating patent assertion suits against competitors, counseling biosimilar developer in pre-litigation matters, and confidential arbitration proceedings involving pharmaceutical IP licensing disputes.

In addition to her IP work, Ms. Grammel was also one of the Goodwin attorneys on the federal trial team that defended former SAC Capital Advisors portfolio manager Mathew Martoma. In the largest-ever insider trading prosecution brought to trial, Mr. Martoma faced charges that he improperly obtained non-public information about the results of a high-profile pharmaceutical clinical trial and used this information to make trades resulting in profit and avoided losses of over $275 million.

Pro Bono

Ms. Grammel devotes a significant portion of her practice to pro bono matters. She has represented indigent clients in various matters including an appeal of eviction proceedings, pursuit of civil rights claims under 42 U.S.C. § 1983, and defense of criminal securities fraud allegations. Ms. Grammel has also assisted legal permanent residents in applying for U.S. citizenship and is currently representing four young girls in their green card applications after obtaining awards of Special Immigrant Juvenile status based on abuse or neglect in their home country.  In 2020 and 2022, Ms. Grammel led teams winning two contested immigration trials, obtaining grants of asylum for Ugandan refugees who fled to the United States following persecution in their home country on the basis of their sexual orientation.

In addition to these matters, in 2017, Ms. Grammel completed a six-month rotation with the Middlesex County District Attorney’s Office. During this time, she first-chaired fifteen trials, including five jury trials. Ms. Grammel also argued dozens of evidentiary and non-evidentiary motions, including successfully arguing for the admissibility of presumptively excluded evidence at a consolidated hearing addressing a group of cases brought in Woburn District Court prior to 2014.

Professional Activities

Ms. Grammel is a member of the Boston Bar Association and the IP Section of the Federal Bar Association.




University of Pennsylvania Law School

(magna cum laude)


University of California, Los Angeles

(magna cum laude, Phi Beta Kappa)



  • Massachusetts


  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court for the District of Massachusetts
  • U.S. Court of Appeals for the First Circuit

Recognition & Awards

Ms. Grammel has been recognized by The Best Lawyers in America Ones to Watch for her work in Litigation - Intellectual Property and Litigation - Patent 2021-2022. 

Ms. Grammel was a recipient of the Levy Scholarship, the University of Pennsylvania Law School’s largest merit award. She served as an Articles Editor for the University of Pennsylvania Journal of Constitutional Law, and was Vice President of the University of Pennsylvania chapter of Lambda Law. Ms. Grammel was also selected as a member of the Penn Law National Trial Competition team in 2013.


Ms. Grammel has contributed to the following publications and presentations: